StockWatch
·

Sumitomo Chemical India Ltd Q1 FY27 Results

SUMICHEMQ1 FY27 Results
Filing
Result:Steady· Market: UpOne-off gainMargin expansionCost led

Beat/Miss: Inline

MetricValueQ4 FY26Q1 FY26
Revenue1.1K Cr55.5%0.6%
Total Income1.1K Cr55.1%1.4%
Expenditure849.28 Cr49.4%0.7%
PBT288.24 Cr95.3%19.8%
Net Profit214.51 Cr92.7%20.4%
OPM24.47%4.84pp3.73pp
NPM19.31%3.76pp3.05pp
EPS4.3092.8%20.4%
View full financials

Chemicals core metric (revenue) was flat YoY (+0.6%) and adjusted PAT grew only ~9% once the one-off insurance claim is stripped out, with margin expansion from cost control but no volume/topline surprise — ordinary, in-line delivery for the sector.

Q1 FY-2027 RESULTS · SUMICHEM

Sumitomo Chemical Q1: consol PAT +20% to ₹215 Cr on margins; revenue flat, one-off aids

PAT +20.45% YoY · revenue +0.62% · margins expanding · inline vs street

27 Jul 2026 · 3 min read
Revenue

₹1,063.35 Cr

+0.62% YoY

PAT (consolidated)

₹214.51 Cr

+20.45% YoY

Net margin

19.31%

+3pp YoY

EPS

₹4.3

Sumitomo Chemical India's Q1 FY27 (June quarter) was a margin-led print on a flat topline. Consolidated revenue was essentially unchanged year-on-year at ₹1,063 Cr (+0.6% vs ₹1,057 Cr in Q1 FY26), while consolidated PAT rose ~20% to ₹214.5 Cr from ₹178.1 Cr. But the headline flatters the underlying trend: the quarter includes a ₹26.90 Cr positive exceptional — a business-interruption insurance claim tied to the 2022-23 Bhavnagar plant fire — that the year-ago quarter did not have. Stripping it out (net of tax), adjusted PAT was roughly ₹195 Cr, or about +9% YoY. So the real story is steady, single-digit profit growth on flat sales, driven by cost control and mix rather than volume: standalone tells the same story (revenue +0.6% to ₹1,054 Cr, PAT +20% to ₹216.5 Cr), so consolidated and standalone do not diverge.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹1,063.35 Cr+55.5%+0.6%
Expenses₹849.29 Cr+49.4%-0.7%
PAT₹214.51 Cr+92.71%+20.45%
Net margin19.31%+3.8pp+3pp
EPS₹4.3+92.8%+20.4%

Margins did the work. Consolidated net margin expanded to ~20.2% (reported) from ~16.9% a year ago, and stays above year-ago even on the adjusted ~18.3%; operating margin firmed to ~21.9% from ~20.7%. The lift came from softer input costs — cost of materials consumed was broadly flat despite a stronger sales mix, and other expenses actually fell YoY (₹110 Cr vs ₹112 Cr) — consistent with management's stated FY27 plan on the Q4 concall to hold sales levels and pass on cost increases product-by-product to defend margins. On that yardstick the quarter is on-plan: revenue held, margins sustained/expanded. Analyst commentary framing FY27 as 15-20% PAT growth is met on the reported number but sits at the top of the range once the one-off is removed — no broker put out a specific June-quarter consensus, so this is best read as in-line delivery rather than a beat.

404.57442.24479.9517.57555.23528.8504-2305-1506-0907-0207-2407-27Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹528.85, up 21.5% over the past month of trading.

₹ Cr
080.08160.17240.2599.79Q4 FY25rev ₹679 Cr178.1Q1 FY26rev ₹1,057 Cr177.76Q2 FY26rev ₹930 Cr75.8Q3 FY26rev ₹568 Cr111.32Q4 FY26rev ₹684 Cr214.51Q1 FY27rev ₹1,063 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.

What management guided (4 FY-2026 call)
Management expressed cautious optimism for FY27, acknowledging monsoon uncertainty and geopolitical risks which could impact demand and costs. Despite these factors, the company plans to navigate by passing on cost increases systematically and product-by-product, aiming to sustain margins. The focus remains on scaling

This quarter: met

The steep sequential jump (revenue +55%, PAT +93% vs Q4 FY26) is seasonality, not momentum — this is a monsoon-dependent agro-chemicals business whose June (kharif sowing) quarter is structurally its strongest and March its weakest, so QoQ should not be read as acceleration. Two subsidiaries (Barrix Agro Sciences; Excel Crop Care Africa, under liquidation) ran a small net loss (₹1.9 Cr) and remain immaterial. The board also declared the quarter alongside the 26th AGM (July 27) and a ₹1.30 dividend (ex-date July 17). The glyphosate Pest-Control-Operator notification overhang persists but remains stayed by the Delhi High Court pending disposal.

  • W1

    Underlying (ex-one-off) PAT trajectory: adjusted ~+9% YoY needs topline to turn positive for FY27 to hit the 15-20% PAT-growth expectation

  • W2

    Margin durability: NPM held ~18%+ adjusted this quarter — watch whether input-cost pass-through sustains it as monsoon/demand conditions shift over H1

  • W3

    Revenue re-acceleration: management guided to hold current sales levels in FY27 with incremental capex revenue only from FY28 — watch for any deviation from flat topline

Statement in ₹ Million, converted to ₹ Cr (÷10). Current quarter includes a POSITIVE exceptional item of ₹26.90 Cr (Rs 268.96 M insurance claim, Bhavnagar plant fire, business interruption) added back above PBT; year-ago Q1 FY26 had no exceptional. Consol PAT ₹214.51 Cr is total incl NCI; owners' share ₹214.83 Cr, non-controlling interest −₹0.32 Cr (subsidiary losses). Q4 FY26 comparator is a balancing figure. Q1 is the seasonal peak (kharif) so QoQ jumps are seasonality.

Informational and educational content only. Not investment advice.

Sumitomo Chemical India Ltd (SUMICHEM) Q1 FY27 Results — StockWatch